Understanding how a specific protein affects the harmfulness of Pseudomonas aeruginosa
Contribution of CdiA to Pseudomonas aeruginosa pathobiology
This study is looking at how a protein called CdiA helps the bacteria Pseudomonas aeruginosa become more harmful, which could lead to new ways to treat tough infections that don't respond to antibiotics.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Loyola University Chicago NIH-funded |
| Lab location | 1 site (Maywood, United States) |
| Project ID | NIH-11086771 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called CdiA in making Pseudomonas aeruginosa, a common cause of serious infections, more virulent. By analyzing the genetic makeup of various clinical strains, the researchers aim to identify factors that enhance the bacteria's ability to cause disease. They use a mouse model to compare how different strains behave based on the presence of specific genes, focusing on how CdiA contributes to the bacteria's competitive advantage against other microorganisms. The goal is to uncover new therapeutic targets to combat antibiotic-resistant infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from severe infections caused by Pseudomonas aeruginosa, particularly those with antibiotic-resistant strains.
Not a fit: Patients with infections caused by other types of bacteria or those who do not have severe infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for infections caused by antibiotic-resistant strains of Pseudomonas aeruginosa.
How similar studies have performed: Other research has shown success in identifying virulence factors in bacteria, making this approach promising but still relatively novel in the context of Pseudomonas aeruginosa.
Where this research is happening
Maywood, United States
- Loyola University Chicago — Maywood, United States (Active)
Researchers
- Principal investigator: Allen, Jonathan P — Loyola University Chicago
- Study coordinator: Allen, Jonathan P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.